Sequential Secures $3.5M for AI-Driven Skin Health Platform

On March 17, 2026, Sequential announced it had raised $3.5 million from its first equity round. Investors include Sparkfood and Corundum Systems Biology, along with Dermazone Holdings and others. This funding brings Sequential’s total to $7.5 million.

The company focuses on advancing skin health using a non-invasive testing platform to transform biological data into actionable insights. By combining microbial and molecular analyses, Sequential supports the development of effective and trustworthy skin products.

With over 50,000 samples and 4,000+ ingredients in its dataset, Sequential aims to build an AI-powered discovery engine. This new funding will aid in predicting and optimizing next-gen health ingredients.

Sequential’s CEO, Oliver Worsley, emphasizes the potential of AI in dermatological health, moving beyond formulation improvements. Sequential plans to expand its biomarker discovery programs and global partnerships, setting a new standard for data-driven personal care innovation.